Amicus’ oral Fabry disease drug approved in US
Decision follows approval in Europe
Alnylam’s Onpattro is first ever FDA-approved RNAi drug
Onpattro will cost $450,000 a year
11/06/2017
Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard
A unique example of partnership working across the health system, focusses on the service at large, not just the pill, and uses leading-edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore, it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence-based and patient-centric approach to service redesign and resource optimisation.
IATA’s CEIV-Pharma Certification or HSA’s GDP Certification?
13th Cold Chain Distribution Conference
The long road to vaccination by the MSF
Cold Chain Distribution
